levonorgestrel [oral contraceptive] (NORPLANT)

No Proven Advantage for the New Combined Birth Control Pill Drospirenone and Estetrol (NEXTSTELLIS)
July 2023
A 28-day, fixed-dose, combined oral contraceptive marketed as NEXTSTELLIS has no proven advantage over older, well-studied, combined oral contraceptives. Public Citizen’s Health Research Group has designated Nextstellis as a Do Not Use medication, consistent with our designation of other drospirenone-containing combined oral contraceptives.

NUVARING: Do Not Use
April 2014
Do not use the contraceptive drug NUVARING. Multiple studies have shown increased risk of blood clotting with drugs from the same family as NUVARING, and some have shown increased risk with NUVARING itself. Learn about safer, equally effective forms of contraception that are widely available.